PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
32392664-7	2020	RESULTS: In multivariate logistic regression, significantly increased risk of lung cancer was observed for MDM2 SNP309 in the dominant model (TG + GG vs. TT: OR, 2.13; 95% CI, 1.29 to 3.53).	snp309	112-118	MDM2 proto-oncogene	Homo sapiens	107-111
33202864-6	2020	A possible synergism was observed with SNP309 in promoter P2 of MDM2.	snp309	39-45	MDM2 proto-oncogene	Homo sapiens	64-68
32392664-8	2020	Stratification analysis revealed that age, sex, obesity, and smoking also increases the risk of lung cancer when carrying the MDM2 SNP309.	snp309	131-137	MDM2 proto-oncogene	Homo sapiens	126-130
24870800-5	2014	Bioinformatics predicts that the T to G substitution at SNP309 generates a stronger E2F1 binding site, which was confirmed by ChIP and luciferase assays.	snp309	56-62	E2F transcription factor 1	Homo sapiens	84-88
26926790-0	2016	Homozygous G/G variant of SNP309 in the human MDM2 gene is associated with earlier tumor onset in Caucasian female renal cell carcinoma patients.	snp309	26-32	MDM2 proto-oncogene	Homo sapiens	46-50
24870800-11	2014	E2F1 might act as an important factor for SNP309 serving as a rate-limiting event in carcinogenesis.	snp309	42-48	E2F transcription factor 1	Homo sapiens	0-4
23912932-0	2013	Current evidence on the relationship between SNP309 polymorphism in the MDM2 gene and colorectal cancer risk.	snp309	45-51	MDM2 proto-oncogene	Homo sapiens	72-76
22487911-1	2012	Conflicting reports exist regarding the contribution of SNP309 in MDM2 to cancer risk.	snp309	56-62	MDM2 proto-oncogene	Homo sapiens	66-70
23506213-5	2013	The functionality of MDM2 SNP309, with or without H. pylori lipopolysaccharide (LPS), was examined by dual-luciferase assay.	snp309	26-32	MDM2 proto-oncogene	Homo sapiens	21-25
17575151-6	2007	We show that MDM2 SNP309 rendered a panel of cancer cell lines that are homozygous for SNP309 selectively resistant (approximately 10-fold) to certain TopoII-targeting chemotherapeutic drugs (etoposide, mitoxantrone, amsacrine, and ellipticine).	snp309	18-24	transformed mouse 3T3 cell double minute 2	Mus musculus	13-17
21706156-0	2012	MDM2 SNP309 and TP53 R72P associated with severe and febrile neutropenia in breast cancer patients treated with 5-FU/epirubicin/cyclophosphamide.	snp309	5-11	MDM2 proto-oncogene	Homo sapiens	0-4
22134502-0	2012	MDM2 SNP309 modifies the prognostic significance of the p53 mutational             status in patients with ovarian cancer.	snp309	5-11	MDM2 proto-oncogene	Homo sapiens	0-4
22134502-0	2012	MDM2 SNP309 modifies the prognostic significance of the p53 mutational             status in patients with ovarian cancer.	snp309	5-11	tumor protein p53	Homo sapiens	56-59
19954744-4	2010	MDM2 SNP309 is also associated with HCC.	snp309	5-11	MDM2 proto-oncogene	Homo sapiens	0-4
19954744-5	2010	However, the role of SNP309 in hepatocarcinogenesis with respect to TP53 mutations is unknown.	snp309	21-27	tumor protein p53	Homo sapiens	68-72
18804411-0	2009	MDM2 SNP309 does not confer an increased risk to oral squamous cell carcinoma but may modulate the age of disease onset.	snp309	5-11	MDM2 proto-oncogene	Homo sapiens	0-4
18976073-10	2008	CONCLUSIONS: Although the MDM2 SNP309 does not portend decreased survival, the increased incidence of the mutant G allele in patients with GBM and its influence on age of onset suggest a potential role in the molecular pathogenesis of GBM, and may be a therapeutic target.	snp309	31-37	MDM2 proto-oncogene	Homo sapiens	26-30
18618574-10	2008	The p53 overexpression was associated with MDM2 SNP309.	snp309	48-54	tumor protein p53	Homo sapiens	4-7
18618574-10	2008	The p53 overexpression was associated with MDM2 SNP309.	snp309	48-54	MDM2 proto-oncogene	Homo sapiens	43-47
18575717-9	2008	MDM2 SNP309 and p53 Arg72Pro polymorphisms might influence the clinical outcome of TCCB in a distinctive way between superficial TCCB and invasive TCCB.	snp309	5-11	MDM2 proto-oncogene	Homo sapiens	0-4
18423915-9	2008	The combination of MDM2 SNP309 G/G and p53 codon 72 Arg/Arg polymorphism is associated with the worst OS and DFS.	snp309	24-30	MDM2 proto-oncogene	Homo sapiens	19-23
21268124-9	2011	MDM2 SNP309 may be used as one of the candidate biomarkers to predict NSCLC survival.	snp309	5-11	MDM2 proto-oncogene	Homo sapiens	0-4
21229604-0	2011	Role of the MDM2 SNP309 polymorphism in the initiation and early age of onset of nasopharyngeal carcinoma.	snp309	17-23	MDM2 proto-oncogene	Homo sapiens	12-16
19996219-10	2009	SNP309 was significantly associated with increased sensitivity to alkylating agents and topoisomerase I inhibitors in the cells with wild-type TP53.	snp309	0-6	tumor protein p53	Homo sapiens	143-147
18725577-0	2008	SNP309 as predictor for sensitivity of CLL cells to the MDM2 inhibitor nutlin-3a.	snp309	0-6	MDM2 proto-oncogene	Homo sapiens	56-60
18426989-0	2008	MDM2 SNP309 and TP53 Arg72Pro interact to alter therapy-related acute myeloid leukemia susceptibility.	snp309	5-11	MDM2 proto-oncogene	Homo sapiens	0-4
18262501-0	2008	Influence of MDM2 SNP309 alone or in combination with the TP53 R72P polymorphism in oligodendroglial tumors.	snp309	18-24	MDM2 proto-oncogene	Homo sapiens	13-17
17080308-8	2007	Overall, our data suggest that MDM2 SNP309 accelerates familial breast carcinogenesis, but that this acceleration is not influenced by estrogen signaling.	snp309	36-42	MDM2 proto-oncogene	Homo sapiens	31-35
17527046-8	2007	In our study population, SNP309 affected MDM2 protein level, but had no significant involvement in glioma tumorigenesis.	snp309	25-31	MDM2 proto-oncogene	Homo sapiens	41-45
16818855-10	2006	CONCLUSION: A strong interaction between SNP309 status and tumor p53 status appears to modify the association between p53 status and breast cancer survival.	snp309	41-47	tumor protein p53	Homo sapiens	65-68
17363597-4	2007	The effect of SNP309 upon the p53-MDM2 oscillation was examined in various human cell lines and the oscillations were observed in the cells with at least one wild-type allele for SNP309 (T/T or T/G) but not in cells homozygous for SNP309 (G/G).	snp309	14-20	tumor protein p53	Homo sapiens	30-33
17363597-4	2007	The effect of SNP309 upon the p53-MDM2 oscillation was examined in various human cell lines and the oscillations were observed in the cells with at least one wild-type allele for SNP309 (T/T or T/G) but not in cells homozygous for SNP309 (G/G).	snp309	14-20	MDM2 proto-oncogene	Homo sapiens	34-38
17308077-12	2007	Our results support the role of MDM2-SNP309 as a genetic modifier in LFS.	snp309	37-43	MDM2 proto-oncogene	Homo sapiens	32-36
16818855-10	2006	CONCLUSION: A strong interaction between SNP309 status and tumor p53 status appears to modify the association between p53 status and breast cancer survival.	snp309	41-47	tumor protein p53	Homo sapiens	118-121
16478747-2	2006	SNP309 induces an increase in the level of Mdm2 protein, which causes attenuation of the p53 pathway.	snp309	0-6	MDM2 proto-oncogene	Homo sapiens	43-47
16707433-0	2006	MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner.	snp309	5-11	MDM2 proto-oncogene	Homo sapiens	0-4
16478747-2	2006	SNP309 induces an increase in the level of Mdm2 protein, which causes attenuation of the p53 pathway.	snp309	0-6	tumor protein p53	Homo sapiens	89-92
16141004-3	2005	SNP309 was shown to result, via Sp1, in higher levels of MDM2 RNA and protein, and subsequent attenuation of the p53 pathway.	snp309	0-6	MDM2 proto-oncogene	Homo sapiens	57-61
16141004-3	2005	SNP309 was shown to result, via Sp1, in higher levels of MDM2 RNA and protein, and subsequent attenuation of the p53 pathway.	snp309	0-6	tumor protein p53	Homo sapiens	113-116